Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Long-term outcomes from the JAVELIN Bladder 100 trial in older patients (pts)

被引：4
|
作者：
Gupta, S. [1 ]
Climent Duran, M. A. [2 ]
Sridhar, S. [3 ]
Powles, T. B. [4 ]
Bellmunt, J. [5 ]
Tyroller, K. [6 ]
Guenther, S. [7 ]
di Pietro, A. [8 ]
Grivas, P. [9 ]
机构：
[1] Cleveland Clin Fdn, Taussig Canc Inst, Cleveland, OH USA
[2] Inst Valenciano Oncol, Valencia, Spain
[3] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada
[4] Queen Mary Univ London, Barts Canc Inst, Expt Canc Med Ctr, St Bartholomews Hosp, London, England
[5] Dana Farber Canc Inst, Harvard Med Sch, Dept Med Oncol, Boston, MA USA
[6] EMD Serono Res & Dev Inst Inc, Billerica, MA USA
[7] Merck Healthcare KGaA, Darmstadt, Germany
[8] Pfizer Srl, Milan, Italy
[9] Univ Washington, Fred Hutchinson Canc Ctr, Seattle, WA USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.1020
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2371P
引用
收藏
页码：S1207 / S1207
页数：1
相关论文
共 50 条
  • [1] Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Long-term outcomes from the JAVELIN Bladder 100 trial in patients (pts) with histological subtypes
    Loriot, Yohann
    Gupta, Shilpa
    Powles, Thomas
    Grivas, Petros
    Petrylak, Daniel P.
    Tyroller, Karin
    Jacob, Natalia
    Hoffman, Jason
    Bellmunt, Joaquim
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [2] Long-term safety of avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC) in the JAVELIN Bladder 100 trial.
    Bellmunt, Joaquim
    Aragon-Ching, Jeanny B.
    Climent, Miguel Angel
    Sridhar, Srikala S.
    Powles, Thomas
    Cislo, Paul
    Michelon, Elisabete
    Di Pietro, Alessandra
    Grivas, Petros
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [3] Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Long-term outcomes from the JAVELIN Bladder 100 trial in patients (pts) with high body mass index (BMI)
    Aragon-Ching, Jeanny B.
    Petrylak, Daniel P.
    Sridhar, Srikala S.
    Gupta, Shilpa
    Grivas, Petros
    Powles, Thomas
    Gurney, Howard
    Jacob, Natalia
    Tyroller, Karin
    Guenther, Silke
    Bellmunt, Joaquim
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 600 - 600
  • [4] Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in older patients
    Gupta, S.
    Duran, M. A. Climent
    Sridhar, S. S.
    Powles, T.
    Bellmunt, J.
    Park, S. H.
    Gurney, H.
    Tsuchiya, N.
    Petrylak, D. P.
    Tomita, Y.
    di Pietro, A.
    Manitz, J.
    Tyroller, K.
    Hoffman, J.
    Jacob, N.
    Grivas, P.
    ESMO OPEN, 2025, 10 (04)
  • [5] Avelumab first-line (1L) maintenance in advanced urothelial carcinoma (aUC): Conditional survival and long-term safety in patients (pts) treated for ≥1 or ≥2 years in JAVELIN Bladder 100
    Grivas, P.
    Park, S. H.
    Voog, E.
    Su, W-P.
    Demey, W.
    Fong, P. C.
    Garcia, J. A.
    Jacob, N.
    Gerhold-Ay, A.
    Tyroller, K.
    Hoffman, J.
    Bellmunt, J.
    Powles, T. B.
    ANNALS OF ONCOLOGY, 2024, 35 : S1144 - S1144
  • [6] Genomic biomarkers in peripheral blood (PB) from patients (pts) enrolled in the JAVELIN Bladder 100 trial of avelumab first-line (1L) maintenance in advanced urothelial carcinoma (aUC)
    Powles, T. B.
    Sridhar, S.
    Bellmunt, J.
    Sternberg, C.
    Grivas, P.
    Hunter, E.
    Dezfouli, M.
    Salter, M.
    Powell, R.
    Dring, A.
    Green, J.
    Akoulitchev, A.
    Amezquita, R.
    Ching, K.
    Pu, J.
    Deng, S.
    di Pietro, A.
    Davis, C. B.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1442 - S1442
  • [7] Avelumab first-line maintenance (1LM) for advanced urothelial carcinoma (aUC): Long-term outcomes from JAVELIN Bladder 100 in patients (pts) with low tumor burden
    Bellmunt, Joaquim
    Powles, Thomas
    Park, Se Hoon
    Voog, Eric
    Valderrama, Begona Perez
    Gurney, Howard
    Ullen, Anders
    Loriot, Yohann
    Sridhar, Srikala S.
    Tsuchiya, Norihiko
    Sternberg, Cora N.
    Aragon-Ching, Jeanny B.
    Petrylak, Daniel P.
    Duran, Miguel A. Climent
    Tyroller, Karin
    Hoffman, Jason
    Jacob, Natalia
    Grivas, Petros
    Gupta, Shilpa
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [8] AVELUMAB FIRST-LINE (1L) MAINTENANCE FOR ADVANCED UROTHELIAL CARCINOMA (UC): LONG-TERM OUTCOMES FROM JAVELIN BLADDER 100 IN SUBGROUPS DEFINED BY RESPONSE TO 1L CHEMOTHERAPY
    Valderrama, Begona
    Powles, Thomas
    Sridhar, Srikala
    Caserta, Claudia
    Loriot, Yohann
    Gupta, Shilpa
    Bellmunt, Joaquim
    Sternberg, Cora
    Wang, Jing
    Costa, Nuno
    Laliberte, Robert
    di Pietro, Alessandra
    Park, Se Hoon
    Grivas, Petros
    JOURNAL OF UROLOGY, 2023, 209 : E244 - E244
  • [9] Avelumab first-line (1 L) maintenance for advanced urothelial carcinoma (aUC): long-term outcomes from JAVELIN Bladder 100 in subgroups defined by response to 1 L chemotherapy
    Valderrama, Begona P.
    Powles, Thomas
    Sridhar, Srikala S.
    Caserta, Claudia
    Loriot, Yohann
    Gupta, Shilpa
    Bellmunt, Joaquim
    Sternberg, Cora N.
    Pook, David W.
    Wang, Jing
    Costa, Nuno
    Laliberte, Robert J.
    di Pietro, Alessandra
    Park, Se Hoon
    Grivas, Petros
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 139 - 139
  • [10] Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Longterm outcomes from JAVELIN Bladder 100 in subgroups defined by response to 1L chemotherapy.
    Perez-Valderrama, Begona
    Powles, Thomas
    Sridhar, Srikala S.
    Caserta, Claudia
    Loriot, Yohann
    Gupta, Shilpa
    Bellmunt, Joaquim
    Sternberg, Cora N.
    Wang, Jing
    Costa, Nuno
    Laliberte, Robert J.
    Di Pietro, Alessandra
    Park, Se Hoon
    Grivas, Petros
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345